SLDB Company Overview:
Solid Biosciences Inc. (NASDAQ:SLDB) is a Cambridge, Massachusetts-based biotech focused on the development of a therapy that will cure Duchenne muscular dystrophy (DMD). The company has one asset (SGT-001) that is currently being evaluated in a Phase 1/2 study. Solid Bio was formed in 2014 and went public in 2018, raising net proceeds of $129.3 million at $16 per share. After peaking at an intraday high of $54.84 in June 2018, its shares have plummeted back to busted IPO territory, closing the April 9, 2021 trading session at $5.21 per share, translating to a market cap of $568 million when effect is given to pre-funded warrants.
